While utilizing inhibitors of the canonical TGF-β pathway appears effective against certain aspects of endothelial damage the approach will have to be further tested using other cardiovascular cell types and models of Dox cardiomyopathy in order to overcome the limitation of this study that was performed using preclinical models [84]. Here, TGFB1 is linked to cardiomyopathy.